Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: September 30, 2022 Report Code: GDGMDHC22341IDB-ST

Select Item

The risk factors of Methicillin-Resistant Staphylococcus Aureus (MRSA) are hemodialysis, weakened immune system, admission to hospitals, and wounds. Symptoms include skin rashes, fatigue, chest pain, fever, and swelling. MRSA can be managed using antibiotics and by maintaining hygienic conditions

The Methicillin-Resistant Staphylococcus Aureus pipeline market research report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus Aureus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus Aureus and features dormant and discontinued projects.

MRSA Infections Pipeline Products Market Segmentation by Targets

The key targets in the MRSA infections pipeline products market are Bacterial Cell Membrane, 23S Ribosomal RNA, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI, Peptidoglycan, Bacterial Cell Wall, DNA Gyrase, Staphylococcus aureus Accessory Gene Regulator A, 30S Ribosomal Subunit, Cell Membrane, DNA Topoisomerase IV, and others.

MRSA Infections Pipeline Products Market Analysis by Targets

MRSA Infections Pipeline Products Market Analysis by Targets

For more target insights into the MRSA infections pipeline products market, download a free report sample

MRSA infections Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the MRSA infections pipeline products market are Bacterial Cell Membrane Disruptor, 23S Ribosomal RNA Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI Inhibitor, Peptidoglycan Inhibitor, Bacterial Cell Wall Disruptor, DNA Gyrase Inhibitor, Staphylococcus aureus Accessory Gene Regulator A Inhibitor, 30S Ribosomal Subunit Inhibitor, Cell Membrane Disruptor, DNA Topoisomerase IV Inhibitor, and others.

MRSA Infections Pipeline Products Market Analysis by Mechanisms of Action

MRSA Infections Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the MRSA infections pipeline products market, download a free report sample

MRSA Infections Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the MRSA infections pipeline products market are oral, intravenous, topical, nasal, inhalational, ophthalmic, parenteral, cutaneous, intramuscular, transdermal, and vaginal.

MRSA Infections Pipeline Products Market Analysis by Routes of Administration

MRSA Infections Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights into the MRSA infections pipeline products market, download a free report sample

MRSA Infections Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the MRSA infections pipeline products market are small molecule, synthetic peptide, monoclonal antibody, subunit vaccine, biologic, recombinant protein, recombinant enzyme, vaccine, fusion protein, recombinant peptide, and others.

MRSA Infections Pipeline Products Market Analysis by Molecule Types

MRSA Infections Pipeline Products Market Analysis by Molecule Types

For more molecule type insights into the MRSA infections pipeline products market, download a free report sample

Competitive Landscape

Some of the leading players in the MRSA infections pipeline products market are Acticule Life Sciences Ltd, Curza Global LLC, LegoChem Biosciences Inc, MicuRx Pharmaceuticals Inc, Wockhardt Ltd, Bharat Biotech Ltd, BioPlx Microbiomics Pvt Ltd, Cellics Therapeutics Inc, Destiny Pharma Plc, and Helperby Therapeutics Group Ltd.

MRSA Infections Pipeline Products Market Analysis by Players

MRSA Infections Pipeline Products Market Analysis by Players

To know more about the leading players in the MRSA infections pipeline products market, download a free report sample

MRSA Infections Pipeline Products Market Report Overview

Key Targets Bacterial Cell Membrane, 23S Ribosomal RNA, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI, Peptidoglycan, Bacterial Cell Wall, DNA Gyrase, Staphylococcus aureus Accessory Gene Regulator A, 30S Ribosomal Subunit, Cell Membrane, DNA Topoisomerase IV, and Others
Key Mechanisms of Action Bacterial Cell Membrane Disruptor, 23S Ribosomal RNA Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI Inhibitor, Peptidoglycan Inhibitor, Bacterial Cell Wall Disruptor, DNA Gyrase Inhibitor, Staphylococcus aureus Accessory Gene Regulator A Inhibitor, 30S Ribosomal Subunit Inhibitor, Cell Membrane Disruptor, DNA Topoisomerase IV Inhibitor, and Others
Key Routes of Administration Oral, Intravenous, Topical, Nasal, Inhalational, Ophthalmic, Parenteral, Cutaneous, Intramuscular, Transdermal, and Vaginal
Key Molecule Type Small Molecule, Synthetic Peptide, Monoclonal Antibody, Subunit Vaccine, Biologic, Recombinant Protein, Recombinant Enzyme, Vaccine, Fusion Protein, Recombinant Peptide, and Others
Leading Players Acticule Life Sciences Ltd, Curza Global LLC, LegoChem Biosciences Inc, MicuRx Pharmaceuticals Inc, Wockhardt Ltd, Bharat Biotech Ltd, BioPlx Microbiomics Pvt Ltd, Cellics Therapeutics Inc, Destiny Pharma Plc, and Helperby Therapeutics Group Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Diseases).
  • The pipeline guide reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Diseases) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Diseases)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Diseases).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

AbbVie Inc
Acticule Life Sciences Ltd
Acurx Pharmaceuticals Inc
AEON Medix Inc
AimMax Therapeutics Inc
AlphaMab Co Ltd
Amicrobe Inc
Amprologix Ltd
AnyGen Co Ltd
Aphios Corp
Aridis Pharmaceuticals Inc
Arietis Corp
Aurigene Discovery Technologies Ltd
Basilea Pharmaceutica Ltd
Bharat Biotech Ltd
Biomendics LLC
BioPlx Microbiomics Pvt Ltd
Bioseka UAB
Bioversys AG
Botanix Pharmaceuticals Ltd
Cantab Anti-infectives Ltd
Cellics Therapeutics Inc
Centivax Inc
Chengdu Olymvax Biopharmaceuticals Inc
Crestone Inc
CrystalGenomics Inc
CSA Biotechnologies LLC
Curza Global LLC
Daiichi Sankyo Co Ltd
Debiopharm International SA
DeNovaMed Inc
Destiny Pharma Plc
Eagle Pharmaceuticals Inc
Enesi Pharma Ltd
ESA Patentverwertungsagentur Sachsen-Anhalt GmbH
Exbaq LLC
Global BioLife Inc Ltd
Helperby Therapeutics Group Ltd
Histogen Inc
Hsiri Therapeutics LLC
HyPharm GmbH
ImmunArtes LLC
Immupharma Plc
Inimmune Corp
Integrated BioTherapeutics Inc
ioGenetics Inc
Johnson & Johnson
KBP Biosciences Co Ltd
Lakewood-Amedex Inc
Lead Discovery Center GmbH
LegoChem Biosciences Inc
Lysimmune BioScience
Lyticon LLC
Madam Therapeutics BV
Matrisys Bioscience Inc
Meiji Seika Pharma Co Ltd
MGB Biopharma Ltd
Microbiotix Inc
MicuRx Pharmaceuticals Inc
Naicons Srl
Neupharma Srl
Novabiotics Ltd
Novalex Therapeutics Inc
NovoBiotic Pharmaceuticals LLC
Olgram SAS
Opal Biosciences Ltd
Oppilotech Ltd
Oragenics Inc
Oryn Therapeutics
Oxford Drug Design Ltd
Peptineo
Pharma Holdings AS
Phico Therapeutics Ltd
Prokaryotics Inc
Prommune Inc
Q2 Pharma Ltd
QureTech Bio AB
Recce Pharmaceuticals Ltd
Sano Chemicals Inc
Scandion Oncology AS
SciBac Inc
Sentinella Pharmaceuticals Inc
Shanghai Shangyao Xinya Pharmaceutical Co Ltd
Shanghai Space Peptides Pharmaceutical Co Ltd
Sinsa Labs Inc
Skye Bioscience Inc
Sorrento Therapeutics Inc
Synspira Therapeutics Inc
TaeJoon Pharmaceuticals Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
TAXIS Pharmaceuticals Inc
TGV-Inhalonix Inc
Therapeutic Systems Research Laboratories Inc
Theravance Biopharma Inc
Trellis Bioscience Inc
Venomyx Inc
Viosera Therapeutics
Vitas Pharma Research Pvt Ltd
VLP Biotech Inc
Wockhardt Ltd
Yungjin Pharm Co Ltd
Zhuhai Trinomab Biotechnology Co Ltd
Zydus Lifesciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Overview

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Companies Involved in Therapeutics Development

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drug Profiles

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Discontinued Products

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Infectious Disease reports
Pharmaceuticals
New
Immuno-oncology in pharma: neoepitope prediction
$250 | December 2023
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Pharmaceuticals
New
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
$250 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more